Immuron Limited (IMRN): Buyer most I can get IMRNW..only $1 bid...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	58
Posts	7544
Boards Moderated	0
Alias Born	07/27/2012

Pisd

Re: Pisd post# 140

Thursday, 10/01/2020 12:48:17 PM

Thursday, October 01, 2020 12:48:17 PM

Buyer most I can get IMRNW..only $1 bid gl...

Keep Last Read

Replies (1) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent IMRN News

Immuron Director Resignation • GlobeNewswire Inc. • 05/03/2024 10:00:00 AM
Immuron to host Live Virtual Event • GlobeNewswire Inc. • 04/15/2024 10:00:00 AM
Immuron Travelan® sales continued strong growth • GlobeNewswire Inc. • 04/10/2024 10:00:00 AM
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/07/2024 01:00:20 PM
Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US • GlobeNewswire Inc. • 03/07/2024 11:00:00 AM
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/28/2024 01:08:13 PM
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/21/2024 01:00:38 PM
Immuron Presentation Australian Biologics Festival 2024 • GlobeNewswire Inc. • 02/21/2024 11:00:00 AM
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/13/2024 01:00:12 PM
Immuron achieves record Travelan® sales • GlobeNewswire Inc. • 02/13/2024 11:00:00 AM
Immuron CEO, Steven Lydeamore Investor Webinar Presentation • GlobeNewswire Inc. • 02/08/2024 11:00:00 AM
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/16/2024 01:00:11 PM
Immuron achieves record half yearly Travelan® sales • GlobeNewswire Inc. • 01/16/2024 11:00:00 AM
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/22/2023 12:21:42 PM
Immuron Clinical Trials Update • GlobeNewswire Inc. • 12/22/2023 11:00:00 AM
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/04/2023 11:32:00 AM
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study • GlobeNewswire Inc. • 12/04/2023 11:00:00 AM
Immuron CEO, Steven Lydeamore Investor Webinar Presentation • GlobeNewswire Inc. • 11/28/2023 11:33:14 AM
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/28/2023 11:17:54 AM
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/22/2023 12:16:44 PM
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/21/2023 11:05:20 AM
Immuron CEO Steven Lydeamore Investor Webinar Presentation • GlobeNewswire Inc. • 11/13/2023 11:00:00 PM
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/13/2023 01:28:23 PM
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/30/2023 12:00:17 PM
Immuron CEO Steven Lydeamore presented at AusBioInvest • GlobeNewswire Inc. • 10/30/2023 11:21:17 AM

More IMRN News

InvestorsHub NewsWire

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM

Start posting your company's news

Only $200 per official company press release!

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover